Curcumin, a yellow polyphenol compound found in the Indian spice turmeric (Curcuma longa) demonstrates potent anti-cancer effects against a wide variety of human tumor models in preclinical studies. A major pitfall for the application of curcumin to human cancer therapy has been its limited systemic bioavailability, such that the few clinical trials conducted so far had administered "mega" doses (8-10 grams) of free curcumin daily to patients in order to yield detectable levels. These high dosages significantly affect patient compliance and have stymied the application of this promising, and relatively non-toxic, agent to most visceral malignancies that would mandate high plasma levels of the active therapeutic. A novel nanoparticle encapsulated formulation of curcumin (nanocurcumin) has been engineered which bypasses the bioavailability pitfall of this compound, and enables strikingly higher circulating and tissue levels upon parenteral administration. Nanocurcumin causes significant growth reduction of subcutaneous and orthotopic pancreatic cancer xenografts, and abrogates systemic metastases when co-administered with gemcitabine in a spontaneously metastatic animal model. The studies proposed herein have the overarching goal of performing the efficacy, pharmacokinetics, and toxicity data required for filing an investigational new drug (IND) application with the USFDA. To this effect, nanocurcumin (as single agent or in combination with gemcitabine) will be tested in a panel of low-passage gemcitabine-resistant patientderived orthotopic xenografts (Aim 1) and in a uniformly lethal genetically engineered mouse model (Aim 2), and will undergo "regulatory grade" in vitro and in vivo toxicology testing by the federally-funded Nanotechnology Characterization Laboratory (NCL) (Aim 3), in preparation for a pre-IND application. Two hypothesis-driven aims that integrate unique CCNE resources will also be pursued, including the effects of nanocurcumin on vaccine efficacy and quantifiable measures of cellular immune response (Aim 4;in collaboration with Project 3) and engineering the next generation of active-targeted antibody-conjugated nanocurcumin (Aim 6;in collaboration with the Nanoparticle Engineering and the Validation Cores).

Public Health Relevance

The clinical translation of the promising anti-cancer agent curcumin has been hampered due to poor absorption from the gut. We have generated a nanocurcumin formulation that, for the first time, bypasses this major pitfall, and has the potential to enable widespread application of curcumin to cancer therapy. The studies proposed herein are focused on generating the efficacy and toxicity required to begin clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Song, Xiaolei; Yang, Xing; Ray Banerjee, Sangeeta et al. (2015) Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen. Contrast Media Mol Imaging 10:74-80
Srivastava, Amit K; Bulte, Jeff W M (2014) Seeing stem cells at work in vivo. Stem Cell Rev 10:127-44
Nimmagadda, Sridhar; Pullambhatla, Mrudula; Lisok, Ala et al. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochem Biophys Res Commun 443:635-40
Li, Yang; Foss, Catherine A; Pomper, Martin G et al. (2014) Imaging denatured collagen strands in vivo and ex vivo via photo-triggered hybridization of caged collagen mimetic peptides. J Vis Exp :e51052
Bulte, Jeff W M; Schmieder, Anne H; Keupp, Jochen et al. (2014) MR cholangiography demonstrates unsuspected rapid biliary clearance of nanoparticles in rodents: implications for clinical translation. Nanomedicine 10:1385-8
Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie C et al. (2014) AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res 74:5772-81
Das, Samarjit; Bedja, Djahida; Campbell, Nathaniel et al. (2014) miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS One 9:e96820
Williford, John-Michael; Wu, Juan; Ren, Yong et al. (2014) Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 16:347-70
Shallal, Hassan M; Minn, Il; Banerjee, Sangeeta R et al. (2014) Heterobivalent agents targeting PSMA and integrin-?v?3. Bioconjug Chem 25:393-405
Yang, Xing; Yadav, Nirbhay N; Song, Xiaolei et al. (2014) Tuning phenols with Intra-Molecular bond Shifted HYdrogens (IM-SHY) as diaCEST MRI contrast agents. Chemistry 20:15824-32

Showing the most recent 10 out of 56 publications